The PGE project - The development of the next generation of anti-inflammatory drugs
Indication: rheumatoid arthritis (chronic inflammation)
Targeted mechanism: microsomal prostaglandin E synthase
Founding researcher: Per-Johan Jakobsson and Ralf Morgenstern, Karolinska Institutet
Current status
The PGE project has resulted in a spin-off company, NovaSAID AB. For additional information please see www.novasaid.com. Project management and further development is done by Actar AB on contract basis.